Intellectual impairment: developmental delay – cognitive or language (mild, moderate or severe) · women at risk of preterm birth
Dexamethasone showed no clear difference in intellectual impairment: developmental delay – cognitive or language… compared with betamethasone – child outcomes (moderate certainty).
1 finding from 1 review
Cerebral palsy · women at risk of preterm birth
Dexamethasone showed no clear difference in cerebral palsy compared with betamethasone – child outcomes (low certainty).
1 finding from 1 review
Chorioamnionitis · women at risk of preterm birth
Dexamethasone showed no clear difference in chorioamnionitis compared with betamethasone – maternal outcomes (moderate certainty).
1 finding from 1 review
Maternal puerperal sepsis · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal adverse effects of therapy · women at risk of preterm birth
Dexamethasone showed no clear difference in maternal adverse effects of therapy compared with betamethasone – maternal outcomes (moderate certainty).
1 finding from 1 review
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
Dexamethasone showed no clear difference in any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone – fetal/neonatal outcomes (moderate certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
Dexamethasone showed no clear difference in respiratory distress syndrome compared with betamethasone – fetal/neonatal outcomes (high certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
Dexamethasone showed no clear difference in intraventricular haemorrhage compared with betamethasone – fetal/neonatal outcomes (low certainty).
1 finding from 1 review
Chronic lung disease · women at risk of preterm birth
Dexamethasone showed no clear difference in chronic lung disease compared with betamethasone – fetal/neonatal outcomes (moderate certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
Dexamethasone showed no clear difference in necrotising enterocolitis compared with betamethasone – fetal/neonatal outcomes (low certainty).
1 finding from 1 review
Change in eGFR · preventing the progression of CKD
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with active control (moderate certainty).
1 finding from 1 review
Withdrew due to intolerance ( · preventing the progression of CKD
Metformin showed no clear difference in withdrew due to intolerance ( compared with active control (moderate certainty).
1 finding from 1 review
Dosing and tolerance ( · preventing the progression of CKD
1 finding from 1 review
Kidney failure · preventing the progression of CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
UACR (% change) ( · preventing the progression of CKD
1 finding from 1 review
All‐cause death ( · preventing the progression of CKD
It is very uncertain whether metformin changes all‐cause death ( compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Withdrew due to intolerance ( · preventing the progression of CKD
Metformin probably leads to higher withdrew due to intolerance ( compared with placebo (moderate certainty).
1 finding from 1 review
Dose tolerability ( · preventing the progression of CKD
1 finding from 1 review